Skip to main content
Livermore
Livermore
ZHEN

UBS Group AG

SEC CIK
0001610520
Latest filing
Aug 13, 2026

SGMOQ holding history

Sangamo Therapeutics, Inc in every 13F filed by UBS Group AG, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.

SGMOQ overviewAll 13F holders of SGMOQFull Q2 2026 holdings

Shares (Q2 2026)
0
Sold out in Q2 2026
Value
$0
% of portfolio
0.0%
Quarters held
21
Since Q1 2021
Holdings of SGMOQ by UBS Group AG, by quarter
QuarterSharesValue% of portfolioShare changeActionAll holders
Q2 20260$00.0%−2,570,992−100.0%Sold outHolders
Q1 20262,570,992$635.0K<0.1%+1,546,517+151.0%AddedHolders
Q4 20251,024,475$430.3K<0.1%−296,343−22.4%ReducedHolders
Q3 20251,320,818$888.9K<0.1%+71,809+5.7%AddedHolders
Q2 20251,249,009$675.7K<0.1%+638,043+104.4%AddedHolders
Q1 2025610,966$400.8K<0.1%+276,805+82.8%AddedHolders
Q4 2024334,161$340.8K<0.1%+235,991+240.4%AddedHolders
Q3 202498,170$85.0K<0.1%+12,956+15.2%AddedHolders
Q2 202485,214$30.5K<0.1%−75,086−46.8%ReducedHolders
Q1 2024160,300$107.4K<0.1%+18,111+12.7%AddedHolders
Q4 2023142,189$77.2K<0.1%−603,791−80.9%ReducedHolders
Q3 2023745,980$447.6K<0.1%+649,133+670.3%AddedHolders
Q2 202396,847$125.9K<0.1%−170,766−63.8%ReducedHolders
Q1 2023267,613$471.0K<0.1%−324,441−54.8%ReducedHolders
Q4 2022592,054$1.86M<0.1%+485,785+457.1%AddedHolders
Q3 2022106,269$520.0K<0.1%−91,347−46.2%ReducedHolders
Q2 2022197,616$818.0K<0.1%−262,764−57.1%ReducedHolders
Q1 2022460,380$2.67M<0.1%+51,968+12.7%AddedHolders
Q4 2021408,412$3.06M<0.1%+118,557+40.9%AddedHolders
Q3 2021289,855$2.61M<0.1%+174,571+151.4%AddedHolders
Q2 2021115,284$1.38M<0.1%−230,444−66.7%ReducedHolders
Q1 2021345,728$4.33M<0.1%––Holders

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.